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ABSTRACT
Background: Elevated blood eosinophils have been associated with lower lung function and are believed to
be associated with accelerated lung function decline.
Method: Blood eosinophils were measured in four cohorts: <45 years cohort within the
Vlagtwedde–Vlaardingen (V&V) study, the Uppsala cohort of the European Community Respiratory
Health Survey (ECRHS-Uppsala; <45 years), ⩾45 years cohort within the V&V study, and the Rotterdam
study (⩾45 years). Blood eosinophils at baseline were classified as normal (<300 cells·μL−1) or elevated
(⩾300 cells·μL−1). Lung function was measured at baseline and follow-up with spirometry: forced
expiratory volume in 1 s (FEV1), vital capacity (VC) and their ratio FEV1/VC. The association between
blood eosinophils and lung function was tested cross-sectionally using linear regression and longitudinally
using a mixed model, both adjusted for age, sex, height, pack-years smoking and smoking status. Stratified
analyses were done for asthma.
Results: Elevated blood eosinophils were associated with lower FEV1 (regression coefficient −147 mL (95%
CI −188 to −105 mL)), VC (−120 mL (−165 to −75 mL)) and FEV1/VC (−1.3% (−1.9% to −0.6%)) at
baseline in the two <45 years cohorts, and with lower FEV1 (−70 mL (−112 to −27 mL)) and FEV1/VC
(−1.8% (−2.6% to −1.0%)) in the two ⩾45 years cohorts. Elevated blood eosinophils were associated with
an accelerated decline in FEV1 (−5.5 mL·year−1 (95% CI −10.5 to −0.5 mL·year−1)) and VC (−6.4 mL·year−1
(−11.26 to −1.5 mL·year−1)) compared to normal blood eosinophils in the younger asthmatic subjects in
the longitudinal studies.
Conclusion: Elevated blood eosinophils are associated with lower lung function in the general population
and with an accelerated lung function decline among asthmatic individuals.
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Lung function volumes increase in most subjects until around the age of 15–20 years and starts to decline
around the age of 25 years [1]. An impaired peak lung function as well as an accelerated decline can
contribute to low lung function at a later age [2, 3]. A common cause of accelerated lung function decline
is cigarette smoking, which can lead to chronic obstructive pulmonary disease (COPD) with persistently
reduced forced expiratory volume in 1 s (FEV1) [4] and FEV1/forced vital capacity (FVC) ratio [5].
Accelerated lung function decline is also observed in some asthmatic individuals and has been related to
airway remodelling, with basal membrane thickening, excess mucus production, airway smooth muscle
hyperplasia and epithelial shedding [6], ultimately leading to fixed airflow obstruction with persistently
reduced FEV1 and FEV1/FVC ratio. In COPD, the mechanisms associated with accelerated lung function
decline are probably different from those in asthma and associated to a lesser extent with eosinophil
inflammation [7].
In asthma and COPD, eosinophilic airway inflammation is seen as a specific phenotype with elevated
levels of sputum eosinophils and/or blood eosinophils affecting one-third [8, 9] to half of the patients [10].
Blood eosinophils are associated with sputum eosinophils [11, 12]. Anti-interleukin (IL)-5 therapies, which
almost deplete blood eosinophil levels, reduce exacerbations in patients with severe refractory asthma with
high levels of blood eosinophils [13].
In previous population-based investigations, elevated blood eosinophils have been found to be associated
with lower lung function in the general population [14–16]. In asthmatic populations, elevated blood
eosinophils are likewise associated with lower FEV1, especially when both local and systemic eosinophil
inflammation is present [10, 17]. Over time, some studies have found that a higher blood eosinophil level
is associated with an accelerated lung function decline in the general population [14, 18] and a lower
maximally attained lung function [1]; however, this finding is not consistent across studies [19]. Also in
studies among asthmatic subjects, the associations between blood eosinophil levels and lung function
development have been diverse [18–22]. Hence, it is still unclear whether eosinophilic inflammation is a
driving factor in lung function decline, and whether this association is specific or not for persons with
asthma.
Therefore, we analysed the relation between blood eosinophils and lung function level and decline in four
different population-based cohorts. The cohorts were followed during different decades (from the 1950s to
2010s) both before and after introduction of inhaled corticosteroids (ICS) and with a wide age span to
identify patterns of lung function impairment. Our hypothesis was that elevated blood eosinophils are
associated with a lower lung function level (cross-sectional analysis) and with an accelerated lung function
decline during the follow-up time (longitudinal analysis). Moreover, we stratified our analyses according to
the presence or absence of asthma to see whether it was a common cause of both the accelerated lung
function decline and higher blood eosinophil levels.
Material and methods
Populations
The Vlagtwedde–Vlaardingen study, which began in 1965, took its study population from the two
communities of Vlagtwedde and Vlaardingen in the Netherlands and involved >8000 participants [23, 24].
The study followed up the participants approximately every 3 years, with the maximum number of visits
per participant being eight (at most 25 years of follow-up data). In total, 6684 participants were included
in the cross-sectional analysis, and 3642 were included in the longitudinal analysis (subjects had at least
two spirometry measurements over a period of at least 5 years). The study population was divided into
two separate cohorts, based on their age at baseline: 18–44 years (<45 years) versus 45–74 years
(⩾45 years).
The European Community Respiratory Health Survey (ECRHS) is a multinational European cohort with
three visits: 1991–1992, 1999–2000 and 2011–2012. In this study, eligible participants from the study
centre in Uppsala, Sweden (ECRHS-Uppsala) were included. They were randomly selected and aged
20–44 years, and were included for a questionnaire in 1990. A random sample of 800 subjects was selected
for clinical examination during 1991–1992, and in addition to them, the subjects who had reported
asthma symptoms in the initial questionnaire [25]. In total, 836 subjects were examined, 676 of whom
performed a spirometry test and had blood eosinophils measured at baseline. Of these 676 individuals, 487
subjects participated in at least one of the two follow-ups.
The Rotterdam study is a population-based cohort study that started in 1989 comprising almost 20000
participants aged ⩾45 years, which aimed to assess the occurrence of, and risk factors for, chronic diseases
in the elderly [26]. Every 3–4 years, participants underwent a home interview and clinical examinations at
the research centre. The current study contains participants who visited the Rotterdam research centre
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between 2014 and 2016 (RS-I-6 and RS-II-4) and had an interpretable spirometry and a measured blood
eosinophil count. This population was aged 70–95 years at this follow-up. At that time, 2857 participants
were invited for examination, 1737 of whom were eligible (figure 1).
In all cohorts, smoking status and smoking history were self-reported, and the number of pack-years (one
pack-year corresponding to one pack of 20 cigarettes smoked daily during 1 year) was calculated. Smoking
status was divided into never-, ex- or current smokers.
In the Vlagtwedde–Vlaardingen study, asthma was defined as present when the participant answered yes
to the question “Have you ever had attacks of shortness of breath with wheezing at rest?” In the
ECRHS-Uppsala, current asthma at baseline was defined as present if the subject self-reported a doctor’s
diagnosis of asthma, used asthma medication and/or had an asthma attack in the past 12 months. In the
Rotterdam study, current asthma was defined as asthma diagnosis by a doctor and asthma symptoms and/
or medication in the last 6 months [27].
No information on medication was available in the Vlagtwedde–Vlaardingen study. In the
ECRHS-Uppsala, ICS use or oral corticosteroid (OCS) use was reported for the past 12 months. In the
Rotterdam study, medication prescription data were available through automated pharmacy records. ICS
or OCS use was defined as presence of a prescription within 90 days prior to the date of blood analysis.
Lung function
Pre-bronchodilation values were used for all analyses. In the Vlagtwedde–Vlaardingen study, a
water-sealed spirometer (Lode Spirograph D52, Lode, Groningen, the Netherlands) was used [1]. In the
ECRHS-Uppsala, a dry rolling seal spirometer system (Sensor Medics 2130, Sensor Medics, Anaheim, CA,
USA) was used in the first and second survey, while the NDD Easy One spirometer (NDD




























































































FIGURE 1 Study model. V&V: Vlagtwedde–Vlaardingen; ECRHS: European Community Respiratory Health Survey.
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Screen PFT Pro (Care Fusion Netherlands, Houten, the Netherlands) was used. In the
Vlagtwedde–Vlaardingen study, the FEV1 and inspiratory vital capacity (IVC) was measured and FEV1/
IVC was calculated at all visits. In the ECRHS-Uppsala and Rotterdam studies, FVC was measured. The
term “VC” in the paper refers to IVC in the Vlagtwedde–Vlaardingen study and FVC in the ECRHS or
Rotterdam studies. Predicted FEV1 and FVC values were calculated using the Global Lung Initiative
reference equations [28]. In all cohorts, spirometry was conducted according to the American Thoracic
Society/European Respiratory Society guidelines present at the time of examination.
Blood eosinophils
In the Vlagtwedde–Vlaardingen study, blood eosinophil counts were assessed at baseline in a 1:11 dilution
of peripheral blood with a Bürker counting chamber [29]. In the ECRHS, blood eosinophils were analysed
at baseline on a Hemalog 2R (Technicon Chemicals Company, Tournai, Belgium), in 5 mL blood
supplemented with EDTA (0.34 mol·L−1) [25]. In the Rotterdam study, blood eosinophils were measured
with a Sysmex XS-800 Hematology analyser (Sysmex, Norderstedt, Germany) in blood supplemented with




The four cohorts were cross-sectionally analysed separately in multivariate linear regression analyses with
elevated blood eosinophils compared to normal blood eosinophils as the independent variable and FEV1,
VC and FEV1/VC as outcomes. Inverse variance weighted meta-analyses were conducted on results from
the <45 years Vlagtwedde–Vlaardingen cohort and the ECRHS-Uppsala cohort, and from the ⩾45 years
Vlagtwedde–Vlaardingen cohort and the Rotterdam cohort. The analyses were adjusted for age, sex,
height, weight, smoking and pack-years of cigarette smoking.
Longitudinal analyses
The longitudinal analyses were performed with mixed models, having elevated blood eosinophils as an
independent variable and lung function decline over time, in mL per year (FEV1 and VC) and change in
percent FEV1/VC per year as outcome. Results from the <45 years Vlagtwedde–Vlaardingen cohort and
ECRHS-Uppsala cohort were further meta-analysed using an inverse variance weighted meta-analysis.
Analyses were adjusted for age, sex, height, weight, smoking and pack-years of cigarette smoking. In the
Rotterdam study, blood eosinophils were measured at the most recent study visit, and this cohort was not
longitudinally analysed.
Asthma
To evaluate effect modification by asthma, known to be associated with higher blood eosinophils and
potentially related to an accelerated lung function decline, asthma-stratified regression analyses were
performed both cross-sectionally and longitudinally.
Sensitivity analyses
Analyses for the association between blood eosinophils as a continuous variable (logarithmised) and lung
function were performed both cross-sectionally and longitudinally to evaluate the association, independent
of the chosen blood eosinophil cut-off. Also, analyses with additional adjustments for OCS and ICS use in
the ECRHS-Uppsala and Rotterdam cohorts were performed to evaluate the potential confounding effect
of steroid treatment on the association between blood eosinophils and lung function.
The statistical analyses in the Vlagtwedde–Vlaardingen study were done in SPSS version 23 (released 2015;
IBM SPSS Statistics for Windows, Version 23.0; IBM Corp., Armonk, NY, USA) and in the
ECRHS-Uppsala study in Stata/IC 15.1 (StataCorp, College Station, TX, USA). The analyses in the
Rotterdam study and the meta-analyses were done in R version 3.6.1 (R Foundation for Statistical
Computing, Vienna, Austria).
Ethics
The Vlagtwedde–Vlaardingen study protocol was approved by the Medical Ethics Committee of the
University Medical Centre Groningen, Groningen, The Netherlands. All participants provided informed
written consent.
ECRHS-Uppsala was approved by the Regional Ethical Review Board in Uppsala, Sweden (Dnr. 1991/33;
1999/313; 2010/068), and all participants signed the informed consent.
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The Rotterdam study was approved by the institutional review board (Medical Ethics Committee) of the
Erasmus Medical Centre and by the review board of The Netherlands Ministry of Health, Welfare and
Sports (Dnr. MEC 02.115).
Results
The baseline characteristics of the four cohorts are shown in table 1. The blood eosinophil level was lowest
in the Vlagtwedde–Vlaardingen study and highest in the Rotterdam study. The FEV1 (% pred) was close
to 100% at baseline in the ECRHS and Rotterdam studies; 86% in the <45 years Vlagtwedde–Vlaardingen
cohort and 80% in the ⩾45 years Vlagtwedde–Vlaardingen cohort. The mean age was highest in the
Rotterdam study (78 years). The Vlagtwedde–Vlaardingen <45 years cohort had the highest prevalence of
current smokers, while the ECRHS-Uppsala and ⩾45 years Vlagtwedde–Vlaardingen cohort had the
highest prevalence of never-smokers (50%). The prevalence of asthma was highest in the ECRHS cohort,
which was enriched with asthmatic subjects, at 13%, and lowest in the Vlagtwedde–Vlaardingen cohorts at
3–4% (table 1). The Rotterdam study had 7.7% asthmatic participants. The use of ICS among the
asthmatic individuals was 33% in the ECRHS study and 49% in the Rotterdam study. The baseline
characteristics stratified on asthma are presented in supplementary table S1a and b, and of the subjects
included in the longitudinal analysis in supplementary table S2.
Cross-sectional analysis
In the cross-sectional analysis, elevated blood eosinophils were associated with a lower FEV1 in all cohorts,
with borderline statistical significance (p=0.057) in the Rotterdam study (table 2) and a significant
association in the meta-analyses (figure 2). Moreover, elevated blood eosinophils were associated with a
lower VC in the <45 years cohorts but not in the ⩾45 years cohorts. Elevated blood eosinophils were
associated with a lower FEV1/VC in all cohorts (table 2) and this was also seen in the meta-analyses
(figure 2). Stratified for asthma, the <45 years Vlagtwedde–Vlaardingen cohort showed an association
between elevated blood eosinophils, compared to normal blood eosinophils, and a lower lung function, in
both asthmatic and non-asthmatic individuals, but with larger estimates among asthmatic individuals. In
the ECRHS-Uppsala, there was a significant association between elevated blood eosinophils compared to
normal blood eosinophils and lower lung function only among the non-asthmatic individuals. In the
⩾45 years cohorts, there were associations between elevated blood eosinophils and lower VC among the
asthmatic patients from Vlagtwedde–Vlaardingen, and a lower ratio among the non-asthmatic individuals
from Vlagtwedde–Vlaardingen and a trend in Rotterdam (table 3). In the meta-analyses elevated blood
eosinophils in general were associated with lower lung function estimates in the asthma group; however,
the smaller group size yielded larger confidence intervals (figure 2).
TABLE 1 Characteristics of the cross-sectional study populations
V&V
18–44 years of age
ECRHS-Uppsala
20–45 years of age
V&V
45–74 years of age
Rotterdam
70–95 years of age
Subjects 4881 676 1803 1737
Female 2348 (48%) 341 (50%) 987 (55%) 952 (55%)
Age years 30.3±8.0 33±7.3 53±5.9 78±5.1
Never-smokers 1559 (32%) 338 (50%) 896 (50%) 589 (34%)
Previous smokers 490 (10%) 154 (23%) 146 (8%) 1036 (60%)
Current smokers 2832 (58%) 182 (27%) 761 (42%) 111 (6%)
Pack-years# 4.2 (0.9–11.3) 8.5 (3.2–17) 23.1 (12.9–36.0) 18.1 (6.8–35.0)
Asthma 176 (3%) 90 (13%) 65 (3.6%) 127 (7.5%)
ICS use 38 (6%) 155 (9%)
ICS use, asthmatic individuals 30 (33%) 79 (48%)
OCS use 2 (0.3%) 123 (7%)
OCS use, asthmatic individuals 2 (2%) 26 (16%)
BMI kg·m−2 24.6±3.5 23.3±3.5 27.4±4.0 27.4±4.1
FEV1 % pred 85.9±12.1 102±13 79.5±15.2 97±19
Blood eosinophils¶ cells·μL−1 98±2.7 152±2.1 109±2.6 182±1.9
Blood eosinophils ⩾300 cells·μL−1 412 (8%) 119 (18%) 158 (9%) 369 (21%)
Data are presented as n, n (%), mean±SD or median (interquartile range), unless otherwise stated. V&V: Vlagtwedde–Vlaardingen study;
ECRHS: European Community Respiratory Health Survey; ICS: inhaled corticosteroids; OCS: oral corticosteroids; BMI: body mass index; FEV1:
forced expiratory volume in 1 s; % pred: % predicted. #: among the participants with a history of smoking; ¶: geometric mean±exp.SD.
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Longitudinal analysis
In the longitudinal analysis, no statistically significant associations were seen between elevated blood
eosinophils at baseline and an accelerated lung function decline in the two Vlagtwedde–Vlaardingen cohorts
or in the meta-analyses (figure 3). In the ECRHS-Uppsala, elevated blood eosinophils were associated with
an accelerated FEV1 and VC decline, while FEV1/VC was not significantly affected (table 4). Stratified for
asthma, elevated compared to normal blood eosinophils at baseline was associated with an accelerated VC
decline among asthmatic individuals in the <45 years Vlagtwedde–Vlaardingen cohort, and with an
accelerated FEV1 decline among asthmatic individuals and an accelerated VC decline among the
non-asthmatic individuals in the ECRHS-Uppsala cohort (table 5). The ⩾45 years Vlagtwedde–Vlaardingen
cohort had too few asthmatic subjects to analyse (n=19). In the meta-analyses, an accelerated decline in
FEV1 and VC was seen among the asthmatic individuals, but not the non-asthmatic individuals (figure 3).
Sensitivity analyses
There were only minor differences when blood eosinophils were analysed as a continuous variable in the
cross-sectional (supplementary table S3) and longitudinal analyses (supplementary table S4). In the
ECRHS-Uppsala, adjustment for ICS/OCS resulted in a non-significant association between elevated blood
eosinophils and a lower VC and FEV1/VC in the cross-sectional analysis and a non-significant association
with accelerated VC decline among non-asthmatic individuals in the longitudinal analysis. The association
between elevated blood eosinophils and lower FEV1 became significant (−45 mL, 95% CI −82 to −8 mL)
among the non-asthmatic individuals with adjustment for ICS/OCS in the Rotterdam study.
Discussion
In this study, we investigated the association between elevated blood eosinophils (i.e. ⩾300 cells·µL−1) and
lung function parameters in cross-sectional and longitudinal analyses in four European cohorts. The main
results show an association between elevated blood eosinophils and lower lung function cross-sectionally
in the entire population. Longitudinally, the results were more scattered. Meta-analysed, an association
between elevated blood eosinophils and an accelerated FEV1 and VC decline was found in asthmatic









Vlagtwedde–Vlaardingen <45 years of age, n=4881 −142 (−188 to −96) −120 (−169 to −71) −1.1 (−1.9 to −0.3)
ECRHS-Uppsala, n=676 −167 (−265 to −67) −119 (−231 to −6.5) −1.7 (−3.0 to −0.36)
Vlagtwedde–Vlaardingen ⩾45 years of age, n=2139 −108 (−184 to −32) −40 (−119 to 39) −2.9 (−4.4 to −1.5)
Rotterdam, n=1686 −52 (−104 to 0.4) −12 (−73 to 50) −1.3 (−2.3 to −0.4)
Significant associations in bold. FEV1: forced expiratory volume in 1 s; VC: vital capacity; β: regression coefficient; CI: confidence interval;
ECRHS: European Community Respiratory Health Survey. #: adjusted for previous or current smoking, pack-years, age, sex, height and weight;


































FIGURE 2 Cross-sectional meta-analyses, presenting results for the whole cohort and stratified for asthma. Grey-shaded areas represent the
meta-estimates and 95% confidence intervals for the two <45 years cohorts. FEV1: forced expiratory volume in 1 s; VC: vital capacity (forced VC in
the Rotterdam and European Community Respiratory Health Survey studies, or inspiratory VC in the Vlagtwedde–Vlaardingen study).
https://doi.org/10.1183/23120541.00320-2020 6
LUNG FUNCTION | I. MOGENSEN ET AL.
individuals in the younger cohorts; the non-asthmatic individuals did not have an accelerated lung
function decline either among the younger or older participants.
Cross-sectionally, an association was found between elevated blood eosinophil counts and lower lung
function. The association with the obstructive pattern (lower FEV1 and FEV1/VC ratio) was found in both
the younger and older cohorts. The association between elevated blood eosinophils and lower VC was only
seen in the younger cohorts, suggesting an additional relation with lower lung volumes in younger adults,
as opposed to the older cohorts. This might be explained to some extent by the fact that in young adults
who are still in their growth phase, a higher blood eosinophil level has been linked to a lower peak lung
function [1].
Ageing affects both level of lung function and level of blood eosinophils. Lung function increases with age
until around 15–20 years of age, after which it plateaus until ∼20–25 years of age [1, 31], after which it
decreases, although higher cut-off points have been reported [32]. JACINTO et al. [33] reported that blood
eosinophil levels decreased from 6 years until ∼35 years of age, and then slightly increased with higher age.
The increase of blood eosinophils with age, together with the decline in pulmonary function, might











Vlagtwedde–Vlaardingen <45 years of age, n=176
−385 (−610 to −159) −215 (−414 to −16) −6.1 (−10.3 to −1.8)
No asthma
Vlagtwedde–Vlaardingen <45 years of age, n=4703
−102 (−150 to −55) −106 (−158 to −55) −0.3 (−1.1 to 0.6)
Asthma
ECRHS-Uppsala, n=90
125 (−129 to 381) 67 (−187 to 321) −0.12 (−3.8 to 3.6)
No asthma
ECRHS-Uppsala, n=585
−158 (−269 to −48) −156 (−290 to −23) −0.58 (−2.0 to 0.80)
Asthma
Vlagtwedde–Vlaardingen ⩾45 years of age, n=65
−309 (−687 to 69) −382 (−663 to −102) −5.2 (−14.1 to 3.7)
No asthma
Vlagtwedde–Vlaardingen ⩾45 years of age, n=1738
−53 (−131 to 25) 111 (−32 to 254) −1.8 (−3.2 to −0.3)
Asthma
Rotterdam, n=127
−44 (−217 to 128) 64 (−131 to 260) −2.7 (−6.1 to 0.7)
No asthma
Rotterdam, n=1571
−31 (−87 to 25) −3 (−69 to 64) −0.8 (−1.8 to 0.1)
Significant associations in bold. FEV1: forced expiratory volume in 1 s; VC: vital capacity; β: regression coefficient; CI: confidence interval;
ECRHS: European Community Respiratory Health Survey. #: adjusted for age, height, weight, sex, pack-years, previous and current smoking;

















































FIGURE 3 Longitudinal meta-analyses, presenting results for the whole cohort and stratified for asthma. Grey-shaded areas represent the
meta-estimates and 95% confidence intervals for the two <45 years cohorts. FEV1: forced expiratory volume in 1 s; VC: vital capacity (forced VC in
the Rotterdam and European Community Respiratory Health Survey studies, or inspiratory VC in the Vlagtwedde–Vlaardingen study).
https://doi.org/10.1183/23120541.00320-2020 7
LUNG FUNCTION | I. MOGENSEN ET AL.
account for some of the associations found in the older cohort. However, we tried to account for this by
adjusting for age.
In the longitudinal analyses, only the ECRHS-Uppsala cohort showed an accelerated lung function decline
among the participants with elevated blood eosinophils. The ECRHS-Uppsala cohort had a prevalence of
14% asthmatic individuals who contributed to the longitudinal analysis due to enrichment with subjects
with respiratory symptoms, according to the ECRHS protocol. Asthma is associated with both higher
blood eosinophil levels and an accelerated lung function decline. Indeed, in the stratified analysis for
asthma, the significant association between an elevated blood eosinophil level and an accelerated FEV1
decline was only present among the asthmatic individuals in the ECRHS-Uppsala cohort. Also in the
<45 years Vlagtwedde–Vlaardingen cohort, elevated blood eosinophil levels were associated with an
accelerated VC decline among asthmatic individuals, but not among non-asthmatic individuals.
Surprisingly, no association was seen between elevated blood eosinophils and lower lung function among
the asthmatic individuals in the ECRHS or the Rotterdam cohorts in the cross-sectional analyses, possibly
a consequence of availability of better treatments for inflammation in this era with greater access to ICS.
Earlier studies were inconclusive. In a 20-year study of young adults, HANCOX et al. [18] found higher
blood eosinophil levels to be associated with lower FEV1 and FEV1/FVC, but not with a lower FVC. These
associations were found in both asthmatic and non-asthmatic individuals. However, other investigations









Vlagtwedde–Vlaardingen <45 years of
age, n=2909
0.6 (−0.4 to 1.5) 0.4 (−0.5 to 1.4) −5.7×10−3 (−2.5×10−2 to 1.3×10−2)
ECRHS-Uppsala, n=487 −6.4 (−10.5 to −2.3) −7.2 (−11.9 to −2.4) −3.4×10−2 (−1.1×10−1 to 4.2×10−2)
Vlagtwedde–Vlaardingen ⩾45 years of
age, n=737
0.3 (−1.4 to 2.1) 0.3 (−1.6 to 2.1) −3.4×10−3 (−4.7×10−2 to 4.0×10−2)
Significant associations in bold. FEV1: forced expiratory volume in 1 s; VC: vital capacity; β: regression coefficient; CI: confidence interval;
ECRHS: European Community Respiratory Health Survey. #: adjusted for age, height, weight, sex, pack-years, all in interaction with time;
¶: forced VC in the Rotterdam and ECRHS studies, or inspiratory VC in the Vlagtwedde–Vlaardingen study.
TABLE 5 Asthma-stratified analysis, associations between elevated blood eosinophils (⩾300 cells·μL−1) and excess lung










Vlagtwedde–Vlaardingen <45 years of
age, n=109
−3.8 (−9.4 to 1.9) −5.8 (−11.2 to −0.4) 2.2×10−2 (−1.3×10−1 to 1.7×10−1)
No asthma
Vlagtwedde–Vlaardingen <45 years of
age, n=2797
0.8 (−0.2 to 1.8) 0.7 (−0.2 to 1.7) −3.3×10−3 (−2.2×10−2 to 1.6×10−2)
Asthma
ECRHS-Uppsala, n=70
−12.3 (−23.6 to −0.9) −8.9 (−20.6 to 2.8) −8.2×10−2 (−3.0×10−1 to 1.4×10−1)
No asthma
ECRHS-Uppsala, n=416
−4.0 (−8.5 to 0.5) −6.1 (−11.8 to −0.5) 2.3×10−2 (−5.5×10−2 to 1.0×10−1)
Asthma
Vlagtwedde–Vlaardingen ⩾45 years of
age, n=19
Too few Too few Too few
No asthma
Vlagtwedde–Vlaardingen ⩾45 years of
age, n=717
0.4 (−1.4 to 2.2) 0.2 (−1.8 to 2.1) 1.3×10−3 (−4.3×10−2 to 4.5×10−2)
Significant associations in bold. FEV1: forced expiratory volume in 1 s; VC: vital capacity; β: regression coefficient; CI: confidence interval;
ECRHS: European Community Respiratory Health Survey. #: adjusted for age, height, weight, sex, pack-years, all in interaction with time;
¶: forced VC in the Rotterdam and ECRHS studies, or inspiratory VC in the Vlagtwedde–Vlaardingen study.
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have not found a clear association between higher blood eosinophil levels and accelerated FEV1 decline
[19, 20] or even a slower decline [21, 22]. This is in contrast to the findings in this investigation, where the
accelerated lung function decline was mainly seen in asthmatic individuals with elevated blood eosinophils,
and there was also an effect on the VC.
A strength of this investigation is the inclusion of four large cohorts with both young and old individuals
with and without asthma. For three of the cohorts, we also had follow-up measurements with a follow-up
time of up to 25 years. Interestingly, when analysed with the same method, we found a fairly similar
association between blood eosinophils and lung function in the cohorts analysed cross-sectionally in the
respective age strata, despite differences in composition, time frame and exposures. However, when
stratified for asthma, the associations were heterogeneous. One explanation could be the differences in
asthma diagnosis between Vlagtwedde–Vlaardingen, ECRHS-Uppsala and Rotterdam. Another important
difference is the use of ICS in both the ECRHS-Uppsala and Rotterdam cohorts, but not in the
Vlagtwedde–Vlaardingen cohorts, which were followed up before ICS were commonly used, although
some patients might have received systemic treatment with corticosteroids. Hence, better treatment of
inflammation in the two later studies (ECRHS-Uppsala and Rotterdam) could be the reason for the better
lung function measures among the asthmatic individuals with elevated blood eosinophils in these cohorts
in the cross-sectional analyses. Interestingly, despite this, the <45 years old cohorts had an accelerated lung
function decline among asthmatic individuals with elevated blood eosinophil levels, compared with
asthmatic individuals with normal blood eosinophil levels, with the largest decline in the ECRHS-Uppsala
cohort. In other words, we did not find a reduced lung function decline despite ICS use in about 36% of
the participants with asthma in the ECRHS-Uppsala cohort, as compared to the Vlagtwedde–Vlaardingen
cohort with no ICS use. However, the accelerated decline in VC also among non-asthmatic individuals
with elevated blood eosinophil levels in the ECRHS-Uppsala cohort suggests that this association is not
limited to persons with asthma.
There are some limitations to our study. The blood eosinophil measurements were taken only at one
time-point, but it is known that blood eosinophils vary over time [34]. Further, only pre-bronchodilator
lung function was measured. In subjects with asthma, a low pre-bronchodilator FEV1 could be a sign of
uncontrolled disease and undertreatment associated with temporarily higher blood eosinophil levels. This
would possibly lead to large fluctuations in lung function measurements between the visits. However, the
long follow-up time should to some degree attenuate for the effect of temporal fluctuations. The cohorts
were also followed during different decades and in different countries (Vlagtwedde–Vlaardingen and
Rotterdam studies in the Netherlands and ECRHS-Uppsala in Sweden) with different exposures to
environmental factors that could possibly affect the results. The definitions of asthma and lung function
measures (FVC and IVC) varied among the studies and are further limitations.
In conclusion, this study observed an association between elevated blood eosinophil levels and lower lung
function cross-sectionally. Moreover, elevated blood eosinophils in the younger cohorts were associated
with an overall lower lung function, while in the older cohorts an association with an obstructive pattern
was mainly found. We could not consistently show an accelerated lung function decline related to elevated
blood eosinophil levels, and our stratified analyses for asthma suggested that the association between
elevated blood eosinophils and an accelerated FEV1 decline is generally present in asthmatic individuals,
but not in the general population.
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